Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors

US8084481B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Heinrich Meier · Wuppertal, DE
• Eckhard Bender · Langenfeld, DE
• Ulf Bruggemeier · Leichlingen, DE
• Ingo Flamme · Bergneustadt, DE
• Dagmar Karthaus · Solingen, DE
• Peter Kolkhof · Wuppertal, DE
• Daniel Meibom · Leverkusen, DE
• Dirk Schneider · Wuppertal, DE
• Verena Voehringer · Wolfegg, DE
• Chantal Fürstner · Neheim, DE
• Jörg Keldenich · Wuppertal, DE
• Dieter Lang · Velbert, DE
• Elisabeth Pook · Wuppertal, DE
• Carsten Schmeck · Wuppertal, DE

Key dates

• Filing date: May 21, 2007
• Grant date: Dec 27, 2011
• Expiry date: Dec 2, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.